Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

Delayed Quote. Delayed  - 09/30 10:14:59 pm
402.02 USD   -1.07%
09/30 NASDAQ 100 MOVE : Ctsh, nxpi
09/30 REGENERON PHARM : Announces Phase 2 Study of Aflibercept Co-Formulat..
09/27 FDA GRANTS PRIO : REGN), Sanofi SA (NYSE:SNY)
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 04:44pm CEST
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
09/30 NASDAQ 100 MOVERS : Ctsh, nxpi
09/30 REGENERON PHARMACEUTICALS : Announces Phase 2 Study of Aflibercept Co-Formulated..
09/29 REGENERON PHARMACEUTICALS : and Teva Announce Global Collaboration to Develop an..
09/29 REGENERON PHARMACEUTICALS : Assigned Patent
09/27 FDA GRANTS PRIORITY REVIEW FOR DUPIL : REGN), Sanofi SA (NYSE:SNY)
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/22 REGENERON PHARMACEUTICALS : Assigned Patent
09/20 REGENERON PHARMACEUTICALS : Teva buys rights to Regeneron chronic pain drug for ..
09/20 REGENERON PHARMACEUTICALS INC : Entry into a Material Definitive Agreement (form..
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/30 BIOTECH FORUM DAILY DIGEST : A Volatile Few Days, Some Small Caps Blow Up, Spotl..
09/30 AMGEN GETS BUSY; MANY NEWS ITEMS : Anything Good Yet?
09/30 Regeneron's failed mid-stage study of rinucumab weights on Ophthotech; shares..
09/30 Sanofi announces thematic call on Dupilumab
09/30 Regeneron's Eylea combo no better than Eylea alone in mid-stage study in wet ..
Advertisement
Financials ($)
Sales 2016 5 073 M
EBIT 2016 1 798 M
Net income 2016 731 M
Finance 2016 961 M
Yield 2016 -
P/E ratio 2016 66,74
P/E ratio 2017 45,81
EV / Sales 2016 8,25x
EV / Sales 2017 6,85x
Capitalization 42 787 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 468 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, CEO & Class I Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Class I Director & Chief Scientific Officer
Charles A. Baker Independent Class III Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..-25.15%42 787
AMGEN, INC.1.92%123 816
GILEAD SCIENCES, INC.-23.06%102 749
CELGENE CORPORATION-14.19%79 659
VERTEX PHARMACEUTICALS..-32.45%21 061
ACTELION LTD21.70%18 780
More Results